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Investigating the role of Quaking in antigen uptake and cross-presentation by 
dendritic cells 
Yating Li, B.Sc. 
Advisory Professor: Cassian Yee, M.D. 
Dendritic cells (DCs) are considered the most potent antigen presenting cells 
(APC) due to their superior capability of cross-presenting exogenous antigens to CD8+ 
T cell for strong adaptive immune responses. They internalize foreign antigens by 
phagocytosis, endocytosis or macropinocytosis, which are then processed in 
endosomal compartments and loaded onto MHC Class I molecules. However, the 
molecular mechanisms regulating exogenous antigen uptake and cross-presentation 
by DCs are not fully understood.  
In this study, we discovered that an RNA-binding protein, Quaking (QKI) plays 
a pivotal role in antigen uptake by DCs. Our previous studies in neural stem cells and 
microglia have identified QKI as a novel regulator of phagosomes and endolysosomes, 
and knocking down of QKI significantly downregulates genes involved in phagosome 
maturation and endosome signaling. Furthermore, we have also shown that QKI 
interacts with a nuclear receptor, PPARδ, in multiple cell types. The QKI- PPARδ 
complex induces expression of a large set of genes associated with signaling in 
phagosome and endolysosome by binding to their promoter regions. Therefore, we 
hypothesize that in DCs, QKI and PPARδ mediated promotion of phagosome and 
endolysosome signaling can enhance antigen uptake and cross-presentation function 
of these cells.  
 v 
Using human monocyte derived DCs, we found QKI and PPARδ to be 
significantly upregulated upon monocyte differentiation into DC in vitro. Our data have 
demonstrated that activation of QKI/PPARδ complex by PPARδ receptor agonist 
increases the phagocytosis activity in DCs while siRNA silencing of QKI or PPARδ 
impairs it.  This suggests that QKI cooperates with PPARδ to enhance the antigen 
uptake by DCs. Our studies did not establish the role of either QKI or PPARδ in the 
regulation of exogenous antigen cross-presentation by DCs following uptake.  
Further investigation aimed at dissecting the mechanisms by which QKI/PPARδ 
complex enhances antigen uptake will contribute to our current understanding of DC 
biology and may provide new strategies to improve DC-based immunotherapy. 
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Chapter 1: Introduction 
1.1 Quaking 
Quaking (QKI) is an RNA-binding protein, belonging to the signal transduction 
and activation of RNA (STAR) protein family. It is encoded by the gene qk and has 
three main isoforms (QKI5, QKI6, and QKI-7), generated by alternative splicing (Kondo 
et al., 1999). As an RNA-binding protein, QKI is shown to affect translation, stability, 
export, splicing of mRNA and microRNA biogenesis (Darbelli & Richard, 2016). The 
physiological role of QKI has been mainly studied in the neural system. Ablation of 
expression of QKI in mice impairs the formation of neural tubes and is embryonic lethal 
(Noveroske et al., 2002). While the crucial role of QKI in oligodendrocytes to maintain 
myelination has been established for decades (Hardy, 1998), the detailed mechanism 
was only revealed recently (Zhou et al., 2020). Dysregulation of QKI causes various 
neurological diseases. In ataxia and schizophrenia patients, the expression level of 
QKI is significantly decreased in CNS (Åberg et al., 2006). Furthermore, chromosome 
6q25-6q26 deletion, where qk is located, is found in 30% of glioblastoma cases (Yin et 
al., 2009) indicating the tumor suppressing potential of QKI.  
Using Pten-/-; Trp53-/- mouse model, which develops premalignant neural stem 
cells (NSCs), Shingu et al have demonstrated the functional significance of QKI 
deletion in gliomagenesis. Studies in this model showed that NSC specific deletion of 
qk causes downregulation crucial genes involved in phagosome formation, clathrin-
mediated endocytosis, and endolysosome formation. This causes impairment of 
receptor recycling and endolysosome-mediated protein degradation and subsequently 
results in the sustained expression of proteins involved in self-renewal. This enables 
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glioma stem cells to maintain stemness even outside the niches and permits their 
hyperproliferation during invasion and migration (Shingu et al., 2017). 
Another study investigating the effect of QKI on mature myelin proposed a novel 
mechanism where QKI function is independent of its RNA binding capacity (Zhou et 
al., 2020). Instead, QKI-5 interacts with the PPARδ-RXRα nuclear receptor complex 
as a co-activator, enhancing the expression of genes involved in lipid metabolism, 
particularly fatty acid elongation and desaturation. When QKI is depleted in mouse 
oligodendrocytes, which is essential for myelin production, the lipid component in 
myelin is drastically decreased and results in demyelination-associated disease 
phenotypes. 
Recently, attention have been brought to the role of QKI in immune cells, 
particularly monocytes and macrophages. De Bruin et.al showed that QKI is highly 
expressed in atherosclerotic macrophages and reduction in QKI protein levels impaired 
differentiation of monocytes to macrophage along with a decrease in the uptake of 
lipoproteins by macrophages. The findings were also corroborated in study comparing 
a unique QKI-haploinsufficient atherosclerosis patient with a healthy sibling with intact 
copies of QKI (De Bruin et al., 2016).  
Another study uncovered the anti-inflammatory role of QKI-5 in macrophages. 
It was shown that silencing of QKI-5 in macrophage induces the M1-like polarization, 
that is characterized by an increase in TNF-α and IL-6 production and a decrease in 
IL-10 secretion (L. Wang et al., 2017). Mechanistically, it was found that QKI-5 binds 
and represses NF-κB thereby limiting the STAT1-NF-κB pathway. In mouse model, 
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macrophage-specific depletion of QKI renders them sensitive to endotoxin challenge 
while overexpression of QKI-5 protected the animals against LPS-induced endotoxin 
shock. 
Although novel functions of QKI in monocytes and macrophages have been 
discovered, our understanding of QKI under both physiological and disease conditions 
is still incomplete. Further, besides macrophages, DCs also arise after the 
differentiation of monocytes in response to different stimulus. These monocyte-derived 
dendritic cells play an important role in bridging the innate and adaptive immunity under 
inflammation conditions and are of great therapeutic importance. The contribution of 




Peroxisome proliferator-activated receptor (PPAR) δ, belongs to PPAR nuclear 
receptor family that consists of PPARα, PPARγ, and PPARβ/δ. Members of this 
receptor family largely differ in their tissue distributions, ligand specificities, and 
functions. While PPARα is preferentially expressed in liver, kidney and muscles, and 
PPARγ is mainly found in adipose tissue and macrophage, PPARδ is relatively 
ubiquitously expressed cross various cell types and is the least understood one among 
the three (Biologie & Cellulaire, 1996).  
The crystal structure of PPARδ has been resolved (Zoete et al., 2007) and 
similar to the other two PPARs, it consists of a ligand binding domain (LBD), a DNA 
binding domain, a hinge and two activation function (AF) motifs. The LBD binds to a 
wide variety of ligands, which includes but is not limited to polyunsaturated lipid, 
lipoproteins, and their derivatives. Additionally, synthetic ligands such as GW501516, 
have been developed with high specificity and effectivity with therapeutic potential for 
metabolic diseases. Moreover, the LBD also induces the formation of a heterodimer 
with another nuclear receptor, RXR family receptor. This PPAR/RXR interaction is 
common to all three PPARs and is essential for their functions, which is to modulate 
their targeting genes by binding to PPAR response elements located in the promoter 
regions (Nolte et al., 1998). However, there is also evidence suggesting that PPARδ 
could specifically interact with β-catenin (Scholtysek et al., 2013), or NF-κB instead of 
RXR to regulate a different set of genes (Adhikary et al., 2015). In addition to their 
heterodimer partners, PPARs also interact with co-factors, either co-activators or co-
suppressors, adding another layer of the complexity. The recruitment of co-factors 
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depends on the type of ligand, agonist or antagonist, that induces different 
conformational changes in the LBD and the AF-2 motif, resulting in distinct functions. 
QKI-5 has been found to be one of the co-activators that form a protein complex with 
PPARδ and RXRα to regulate a large set of gene expression in neural stem cells, 
oligodendrocytes and microglia, as mentioned previously (Zhou et al., 2020). 
PPARδ is the least characterized protein among PPARs. Functional 
significance of PPARδ has been mostly focused on fatty acid metabolism and glucose 
homeostasis and knocking out ppard in mice predisposes the development of high fat 
induced obesity (Y. X. Wang et al., 2003). Moreover, treatment with a PPARδ agonist 
enhances insulin secretion and promotes fatty acid oxidation, thereby decreasing body 
fat in mouse. There is also evidence suggesting that PPARδ enhances mitochondrial 
function by promoting expression of genes involved in mitochondria respiration 
(Ravnskjaer et al., 2010).  
The physiological role of PPARδ inflammation has been studied, though with 
contradicting findings. Some studies such as those conducted in EAE mouse model 
revealed its anti-inflammatory role in autoimmune diseases. The PPARδ agonist 
treatment could reduce production of pro-inflammatory cytokines TNFα and MCP-1 
and reduce the disease severity (Dunn et al., 2010). On the contrary, other studies 
have indicated the pro-inflammatory functions of PPARδ. In psoriatic skin condition, 
PPARδ is found to be significantly elevated and induces TNFα secretion (Romanowska 
et al., 2010). Moreover, in monocyte-derived macrophages, PPARδ can bind to NF-κB 
and STAT1 and consequently represses their activation of downstream pro-
inflammatory genes (Adhikary et al., 2015). It is also been shown that deletion of 
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PPARδ in macrophages decreases their phagocytic capacity, thereby limiting their T 
cell activation function (Mukundan et al., 2009). The role of PPARδ in inflammation, 
especially in immune cells, still remains inconclusive.  
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1.3 Dendritic Cells 
Dendritic cells (DCs) are first described by Steinman and Cohn (Steinman & 
Cohn, 1973). They are named after the dendrite-like membrane protrusions. Their 
crucial roles in bridging the innate immunity to adaptive immunity was established in 
later studies. 
DCs constantly survey the environment, detect pathogens, and relay the threat 
to T cells. They express a wide range of pattern recognition receptors (PRRs). PRRs 
can be activated by pathogen-associated molecular patterns (PAMPs) and danger-
associated molecular patterns (DAMPs) that are often found in bacteria, parasites, or 
virus-infected cells. Once DCs get activated by pathogens via PRRs, they present the 
antigens to the T cell through Major Histocompatibility Complex (MHC) molecules. 
Extracellular antigens are internalized, processed into antigenic peptides and loaded 
onto MHC class II molecules for CD4+ T cell activation. In contrast, the intracellular 
antigens are processed and loaded onto MHC class I molecules to specifically bind 
TCRs on CD8+ T cell. In the cases when DCs are not infected by pathogens, they are 
still able to present extracellular antigens to CD8+ T cells through cross-presentation, 
a process that is unique to professional antigen presenting cells (APCs). DCs are not 
the only APCs capable of cross-presentation. Macrophages, B cells, and even a subset 
of endothelial cells under certain circumstances can cross-present and activate CD8+ 
T cells. Yet, DCs facilitate the T cell activation by not only being able to effectively 
present peptide-bound MHC, but also express co-stimulatory molecules and cytokines 
for strong T cell activation (Wculek et al., 2020).  
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DCs at a resting state constantly sample and internalize the surrounding 
environment for evaluation of any potential threat even though no PRRs are activated. 
DCs at this state are considered immature (iDCs). Upon PRR stimulation, iDCs quickly 
upregulate MHC class I and class II expressions, load antigenic peptides on MHC 
molecules and prepare for antigen presentation to T cells. At the same time, co-
stimulatory molecules such as 4-1BBL and OX40L are also increased to provide 
second stimulatory signal for T cells. In addition, depending upon the type of stimulus, 
DCs also secret cytokines, such as IL-4, to modulate naïve T cell differentiation. DCs 
at this stage are called mature DCs (mDCs). 
DCs represent heterogenous populations with different ontogeny and 
physiological roles. They are classified into conventional DCs (cDCs), plasmacytoid 
DCs (pDCs), and inflammatory DCs. cDCs and pDCs are derived from precursor cells 
in the bone marrow whereas inflammatory DCs are differentiated from circulating 
monocytes under inflammation.  
Among different types of DC, cDCs are the major population present at steady 
state. It consists of cDC1 and cDC2 and they are associated with presenting antigens 
to CD8+ and CD4+ T cells, respectively. Their critical role in the induction of protective 
immunity against bacterial and viral infection as well as different types of tumors has 
been extensively studied (Wculek et al., 2020). In contrast, pDCs are known for their 
inability to cross-present antigens at steady state. pDCs are specialized in type I 
interferon production in response to viral infection. Inflammatory DCs can be found at 
the site of injury or infection in vivo. They express high levels of co-stimulatory 
molecules such as CD80, CD86, as well as MHC molecules. In addition, human CD14+ 
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monocytes could be differentiated to DCs ex vivo. These monocyte derived DCs 
(moDCs) exhibit similar transcription profile as in vivo inflammatory DCs, making them 
a good model to study DC biology. In fact, moDCs are widely used in cancer 
immunotherapy as DC vaccines alone or for the ex vivo generation of antigen-specific 
T cells with their anti-tumor effect proven by several clinical trials (Wculek et al., 2020).   
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1.4 Antigen uptake by dendritic cells 
Dendritic cells are considered the most effective antigen presenting cells due to 
their superior ability to stimulate antigen-specific T cell responses. As APC, one of their 
key functions is to constantly sample the external environment and internalize the 
particles outside the cells, ranging from pathogens to apoptotic cells. The route of 
antigen uptake by DCs can be broadly categorized into clathrin-mediated endocytosis, 
phagocytosis, and micropinocytosis.  
1.4.1 Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis is the most extensively studied mode of 
endocytosis, although detailed molecular mechanism studies have not been conducted 
with DCs. This mechanism has been shown to be highly conserved across species 
and different cell types (McMahon & Boucrot, 2011). The process is initiated when a 
membrane invagination is formed, preferentially at the PtdIns(4,5)P2-rich membrane 
region. Upon endocytic receptor activation, a key adaptor protein, AP2 is recruited to 
the membrane curvature and binds to both PIP2 and receptor bound cargo (Höning et 
al., 2005). Clathrin is subsequently recruited to the cargo by AP2 and other adaptor 
proteins followed by quick polymerization into a clathrin-coat that wraps the outer edge 
of the invagination, thereby stabilizing it. As the coated pit extends to its maximal size, 
it internalizes sufficient particles and deforms from the plasma membrane. At this stage 
another protein dynamin is recruited to the neck of the vesicle and induces vesicle 
budding (Kosaka & Ikeda, 1983). When a clathrin-coated vesicle is cleaved off from 
the plasma membrane and fully internalized, HSC70 and Auxilin will dissemble the 
clathrin coat, releasing clathrin back to the cytosol and ready for next round of 
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endocytosis (Massol et al., 2006). Together, a freshly formed endosome is released 
for further trafficking and processing. 
Clathrin-mediated endocytosis is responsible for internalizing a great variety of 
small molecule such as antibodies, lipoproteins and immune-complexes for 
presentation. The functional significance of endocytosis is not limited to antigen 
uptake. Chemokine and cytokine receptors such as CCR5 and IL4 that are highly 
expressed in DCs, are able to induce clathrin-mediated endocytosis to activate 
perspective signaling pathways and to recycle the receptors (McMahon & Boucrot, 
2011).  
1.4.2 Phagocytosis 
In contrast to clathrin-dependent endocytosis, phagocytosis is dependent on 
remodeling of actin cytoskeleton (Freeman & Grinstein, 2014). It is worth noting that 
DC, as well as other professional phagocytes, such as macrophages, constantly 
exhibit filopodia and membrane ruffles, allowing their maximal encounter with the 
environment (Patel & Harrison, 2008). These membrane protrusions are formed by the 
cortical F-actin. Phagocytosis is initiated upon the engagement of a phagocytic 
receptor with targeted particles, leading to the disruption of the steady state actin 
cytoskeleton at the cortical membrane. When F-actin is debranched and nucleated, 
the lateral mobility of other phagocytosis receptors significantly increases, leading to 
an amplified signal for phagocytosis (Jaumouillé et al., 2014). Next, the F-actin 
monomers polymerize and form pseudopodia to internalize the particle. This step 
involves Cdc42, Rho- and Rap-family GTPases that regulate a large number of actin 
nucleation and polymerization proteins such as Arp2/3, coronins, and cofilins, as well 
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as some lipid mediators for protein anchoring (Rohatgi et al., 1999) (Yan et al., 2005) 
(Cai et al., 2007). However, largely due to the complexity of various upstream signals 
from different phagocytosis receptors the detailed molecular mechanisms regulating 
this step are still not completely elucidated. Finally, when the pseudopodia are 
extended to the maximal size and sealed the phagocytosis cup is terminated. At this 
point actin filaments are depolymerized and removed from the nascent phagosome 
(Marion et al., 2012).  
Although formation of a phagosome requires consistent remodeling of the 
cortical cytoskeleton, the initiation driving force and the phagocytosis receptors can 
vary widely. Receptors that induce phagocytosis can be broadly classified into Fc 
receptors, scavenger receptors and integrins, which are all highly expressed in DCs 
(Freeman & Grinstein, 2014). Fc receptors bind to Fc portion of different classes of 
immunoglobulin, thereby recognizing opsonized particles. With their structural 
diversity, scavenger receptors can recognize a wide range of targets. For example, 
CD36 binds to oxidized lipids, commonly found on apoptotic cells (Jaqaman et al., 
2011). Integrins, on the other hands, can be stimulated by not only specific targets 
(both opsonized and non-opsonized), but also by the increase in cellular rigidity (Abram 
& Lowell, 2009). Bacterial cells are thousand times more rigid than normal human cells 
or apoptotic corpses (Tuson et al., 2012). This mechano-signal can be sensed by 
integrins to distinguish between self and non-self-cells.  
Multiple types of phagocytosis receptors can be co-expressed on a single DC. 
While each receptor has distinct selectivity, yet they can overlap extensively. These 
receptors collaborate to recognize a wide range of particles. One of the advantages of 
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this receptor interaction is that enables targeting of several regions recognized by 
different receptors on any particular particle (Uribe-Quero & Rosales, 2017). 
Simultaneous engagement of several receptors enables DCs to detect particles 
present at low concentrations in the environment and enhances the sensitivity of these 
particles for phagocytosis.  
1.4.3 Macropinocytosis 
Apart from clathrin-mediated endocytosis and phagocytosis, DCs also exhibit 
constant engulfment of extracellular milieu in a non-specific manner. This process is 
known as macropinocytosis (Liu & Roche, 2015) (Canton, 2018). Early studies have 
suggested that DCs as well as macrophages actively perform macropinocytosis in a 
relatively large volume and an entire cell can be internalized within an hour. The 
extensive energy spent on macropinocytosis alludes to its functional significance. 
However, compared to other forms of cellular engulfment, macropinocytosis still 
remains a less studied and underappreciated form.  
Unlike endocytosis and phagocytosis which require receptors to recognize 
specific molecules on foreign particles or abnormal cells, macropinocytosis is initiated 
from the membrane ruffles that are induced by a calcium sensing GPCR, CaSR, in 
response to extracellular calcium, which is often elevated at the site of injury or 
infection (Canton et al., 2016). Due to its non-selectivity, a foreign antigen can only be 
internalized only when it is present in high concentrations. However, similar to 
phagocytosis, macropinocytosis also requires actin remodeling and is regulated by 
similar aforementioned actin remodeling machinery (Redka et al., 2018). 
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One of the reasons that macropinocytosis is less understood is that it is 
challenging to target it specifically. For example, inhibitors that prevent actin 
polymerization will simultaneously affect phagocytosis and micropinocytosis making it 
challenging to distinguish the two phenomena. Using different sized fluid tracer or 
dextran also fails to differentiate macropinocytosis from endocytosis due to the overlap 
of particle sizes that they are able to recognize. Some studies employed tagged-OVA 
to evaluate macropinocytosis in DCs. However, later it was shown that tagged-OVA 
can indeed be recognized by mannose receptor to induce phagocytosis (Autenrieth & 
Autenrieth, 2009). Therefore, further studies to differentiate these modes of cellular 
engulfment requires development of highly specific and efficient inhibitors or 
genetically knockout models.  
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1.5 Antigen processing and presentation 
After being internalized, antigens need to be processed to peptides before being 
loaded to the MHC molecules. The size of antigenic peptides is restricted by the 
binding groove of MHC molecules. For MHC class I, this length is restricted to 8 to 11 
amino acids while the number of amino acids in the peptide chain ranges from 14 to 
18 for MHC class II molecules.  
In classical MHC class I presentation, where endogenous antigens are 
presented to CD8+ T cells, antigenic peptides are generated by cytosolic proteasome 
and subsequently recruited to the endoplasmic reticulum (ER) lumen by transporter 
associated with antigen processing (TAP) (Halenius et al., 2015). In the ER lumen, 
TAP forms a peptide-loading complex (PLC) with ERp57, tapasin, calnexin, 
calreticulin, and ER aminopeptidase (ERAP) (Wearsch & Cresswell, 2007). PLC is 
responsible for the final trimming and loading of peptides on MHC class I molecules 
within the ER lumen (Peaper et al., 2005). Following the loading of the peptide, the 
peptide-MHC complex (pMHC) is transported to the cell membrane for T cell activation.  
Loading of exogenous peptides to the MHC class II molecules occurs in a 
specialized endosomal compartment called MHC class II compartment (MIIC) (Roche 
& Furuta, 2015). Pathogens are internalized and temporarily stored in either endosome 
or phagosome (depending on the mode of antigen uptake), which fuses with early 
endosome and then MIIC (Neefjes, 1999). The MIIC is highly acidic and contains 
various lysosomal proteases that can degrade exogenous pathogens. In addition, the 
newly synthesized or recycled MHC class II molecules are also delivered from ER or 
early endosomes to the MIIC, respectively (Griffin et al., 1997). Before reaching the 
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MIIC, MHC class II molecules are associated with the invariant chain (Ii) protein that 
prevents suboptimal loading of random peptides during trafficking. Once inside the 
MIIC, Ii is replaced by Class II-associated Invariant chain Peptide (CLIP). CLIP is not 
removed until the peptide with highest affinity to MHC class II molecules is selected. 
Lastly, the pMHC complex is delivered to the plasma membrane. This trafficking along 
the endocytic pathway is guided by Rab family GTPases. Rab5 marks the newly 
formed endosomes and early endosomes, which is exchanged for Rab7 that marks 
the late endosomes (Bertram et al., 2002). Depletion of either one impairs the fusion 
of endosome with MIIC, thereby reducing MHC class II presentation (Egami et al., 
2014). 
The mechanism for presentation of endogenous antigens has been extensively 
studied and characterized. Yet there is limited understanding of cross-presentation of 
exogenous antigens to MHC class I molecules. To explain this phenomenon, two major 
pathways have been proposed and widely accepted, namely cytosolic and vacuolar 
pathways. However, to what extent these two pathways contribute to the overall cross-
presentation is still debatable and difficult to quantify. Currently most evidence points 
to the cytosolic pathway (Schuette & Burgdorf, 2014). 
In the vacuolar pathway, the internalized antigens remain in the endosomal 
compartments all the time (Joffre et al., 2012). Starting from early endosome or 
phagosome, the fusion with late endosome to exposure of antigens to proteases in the 
lysosome that degrade antigens to antigenic peptides and subsequent loading of the 
peptides to the MHC class I molecules. However, the highly acidic environment in the 
endolysosome is not optimal for antigen loading (Delamarre et al., 2005). Antigenic 
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peptides may be trimmed into individual amino acids before being loaded to MHC class 
I molecules, thereby limiting the cross-presentation. DCs, as potent APCs, have 
evolved mechanisms to overcome these limitations. NADPH oxidase 2 (NOX2) 
consumes proton for ROS production and can thus slow down the acidification 
process. NOX2 is specially recruited to the endosomal compartments in the DCs with 
help from Rab27a and Rac1 (Savina et al., 2006). In addition, V-ATPase is expressed 
to a lower level in DCs compared to other phagocytes, which further reduces the level 
of protons present in the endosomal compartment and enhances the availability of 
peptides for cross-presentation (Savina et al., 2006). Cross-presentation utilizing this 
pathway is sensitive to lysosomal protease inhibitors, such as cathepsin S inhibitor, 
whereas the cytosolic pathway is sensitive to proteasome inhibitors, suggesting the 
involvement of cytosolic proteases in the processing of antigens for cross-presentation.  
The cytosolic pathway requires antigens to be transported from early endosome 
or phagosome to the cytosol. How antigens, which may be large in size, get actively 
transported across endosomal membranes still remains unanswered. Although 
accumulating evidence suggests the involvement of ER associated degradation 
(ERAD) machinery in this process (Ackerman et al., 2006), some studies also support 
the idea that endocytic membrane disruption leads to antigen leakage (Dingjan et al., 
2016). The antigen degradation following transportation to the cytosol is found to hijack 
the mechanism that is utilized by the classical MHC class I presentation. Specifically, 
TAP and ERAP are shown to be responsible for antigen degradation for cross-
presentation. They are found in the endosomes containing peptide-loaded MHC for 
final transport to the plasma membrane. However, this does not exclude the possibility 
that these proteins are recruited to the antigen-containing endosomes before antigen 
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digestion, in which case it is not necessary for antigens to be exported outside 
endosomes for degradation.  
Nevertheless, the crucial role of the Rab family GTPases is not questionable. 
They are involved in sorting, trafficking, and processing of various endosomal 
compartment. A study screening 52 Rab proteins in a murine DC-like cell line revealed 
that 12 of them are essential for antigen cross-presentation (Zou et al., 2009). The 
functional significances of some of them have been reported. For example, Rab27a 
contributes to the incorporation of NOX2 to the endosomes (Jancic et al., 2007). Rab11 
recruits the MHC class I molecules to the antigen-containing phagosomes (Ullrich et 
al., 1996). Rab34 guides the fusion of phagolysosomes (Egami et al., 2014).  
Our current understanding of antigen cross-presentation in DCs remains 
incomplete and the proposed models cannot be fully supported by existing evidence. 
Moreover, many of these studies are conducted in murine system. Whether these 
findings in mouse can be validated in human cells is still unclear and warrants further 





Figure 1: Intracellular pathways for cross-presentation in dendritic cells. 
After being taken up, exogenous antigens are processed in two different pathways. In 
the vacuolar pathway, the antigens are degraded and processed in the 
endosomes/phagosomes by fusing with protease-containing lysosomes and MHC 
Class I-containing recycling endosomes. The exogenous antigens can also be 
exported to the cytosol and degraded by cytosolic proteasomes. Processed antigens 
are transported into ER for MHC Class I loading. Alternatively, they can be transported 
back to endosomes/phagosomes for MHC Class I loading and surface presenting. 
TAP, transporter associated with antigen processing; NOX2, NADPH oxidase 2; 
ERAP, ER-associated aminopeptidase; IRAP, insulin-responsive aminopeptidase.  
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Chapter 2: Materials and Methods 
2.1 Generation of human monocyte derived DCs 
CD14+CD16- monocytes were isolated from previously frozen leukapheresis 
products from healthy donors using EasySepTM human monocyte isolation kit 
according to manufacturer’s instructions (STEMCELL Technologies). Cells were 
cultured in 6-well plates at 0.67 × 106cells/ml in 3 ml of AIM-V containing 800IU/ml of 
GM-CSF and 500 IU/ml of IL-4 for 7 days as previously described (ref). Mature DCs 
were stimulated with 100 ng/ml of LPS for 24 hours before being harvested. 
2.2 Isolation of Peripheral Mononucleocytes (PMN) 
PMNs were isolated from a buffy coat obtained from MD Anderson Blood Bank 
using the gradient centrifugation method. Briefly, in a 50 ml canonical tube, 20 ml of 
diluted blood was layered on top of 10 ml of Histopaque-1077 (Sigma-Aldrich) and 10 
ml of Histopaque-1119 (Sigma-Aldrich). After centrifugation for 30 minutes at 2000 
rpm, the layer between Histopaque-1077 and Histopaque-1119, which contained 
PMNs, was collected. PMNs were washed with RPMI-1640 (Gibco) and counted 
before subjecting them to three rounds of freeze/thaw for cell lysis. 
2.3 Generation of M27 CTLs 
The MART-1 specific cytotoxic T cell lymphocytes (M27 CTLs) was generated 
as previously described (Park et al., 2017). Briefly, PBMCs isolated from leukapheresis 
products were cultured in AIM-V media containing 800 IU/ml of GM-CSF and 500 IU/ml 
of IL-4 for 7 days for generation of DCs. DCs were matured using 2 ng/ml of IL-1β, 
1000 IU/ml of IL-6, 10 ng/ml of TNFα and 1 μg/ml of prostaglandin E2 for at least 18 
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hours. Matured DCs were harvested and pulsed with 40 μg/ml of M27 peptide 
(PolyPeptide Group) and 3 μg/ml of β2-microglobulin (Scripps Laboratories) in PBS 
containing 1% of human serum albumin (Life Technology) for 4 hours at room 
temperature before they were washed and irradiated. Peptide pulsed DCs were 
subsequently used to co-culture with PBMCs at ratio of 1:10 in presence of IL21 and 
low does IL-2. The DC stimulation took two rounds and each round took 7 days. M27-
tetramer+ CD8+ cells were sorted at the end of DC stimulation and expanded using the 
rapid expansion protocol (Park et al., 2017). 
2.4 Co-immunoprecipitation  
Cells were cross-linked in 1% formaldehyde for 10 minutes at 37C and then 
neutralized by Glycine before harvested. Cells were subsequently incubated in 0.3% 
NP-40 lysis buffer supplemented with proteinase inhibitor at 4C for 30 minutes and 
centrifuged for 30 minutes. Cell lysate was sonicated using a Dounce biohomogenizer. 
Protein concentrations were quantified using Bradford Assay (BioRad) as 
manufacturer instructed. Isolated proteins were incubated with indicated antibodies 
overnight at 4C before DynabeadsTM protein G for immunoprecipitation 
(ThermoFisher) was added to the mixture to pull down the QKI-5/PPARδ complex. The 
immunoprecipitation products were subjected for immunoblotting. 
2.5 Immunoblotting 
Cells were harvested, washed with ice-cold PBS and lysed in RIPA lysis buffer 
(ThermoFisher). Protein concentrations were quantified using Bradford Assay 
(BioRad) as manufacturer instructed. 15-30 μg of protein was subjected to SDS-PAGE 
on a NuPAGETM polyacrylamide gel (ThermoFisher) and transferred to a nitrocellulose 
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membrane using the TurboTM Trans Blot system (Bio-Rad). The membrane was 
blocked in 5% non-fat milk overnight 4C and incubated with indicated primary 
antibodies for at least 4 hours. The membrane was then washed and incubated with 
HRP-conjugated secondary antibodies before visualized using SuperSignalTM 
chemiluminescence system (Thermo Fisher). 
2.6 siRNA Knockdown 
Several siRNAs targeting QKI-5 and PPARδ were obtained from Dharmacon. 
N-TERTM Nanoparticle siRNA transfection system was used to transfect 50 nM siRNAs 
to DCs according to manufacturer’s instructions. Transfecting media were removed 24 
hours post transfection and fresh media were replenished.  
2.7 Quantitative RT-PCR 
Cells were harvested and washed three times in PBS before RNA isolation. 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) following manufacturer’s 
instructions. RNA concentration was determined by NanoDrop spectrophotometer 
(ThermoFisher Scientific). The reverse transcription reaction was performed on the 
same amount of RNA across different samples, using the M-MLV Reverse 
transcriptase (ThermoFisher Scientific) as per manufacturer’s instructions. 
Quantitative PCR was performed in duplicates using SYBRTM Select Master Mix 
(Applied Biosystems) and QuantStudio 5 Real-Time PCR System (ThermoFischer 
Scientific) according to manufacturers’ instructions. The housekeeping gene Rpl13a 
was used for normalization. The primers used are listed as follow: Qk forward: 
ATCCTATTGAACCTAGTGGTGTA, reverse: GGTCAGAAGGTCATAGGTTAGTT; 
Ppard forward: CTCTATCGTCAACAAGGACG, reverse: 
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GTCTTCTTGATCCGCTGCAT; Cpt1a forward: CAGGCCGAAAACCCATGTTG, 
reverse: CCACCAGTCGCTCACGTAAT; Pdk4 forward: 
ACAGACAGGAAACCCAAGCC, reverse: TTGCCCGCATTGCATTCTTA; Rpl13a 
forward: CCTCAAGGTCGTGCGTCTGA, reverse; TCCACGTTCTTCTCGGCCTG. 
2.8 Phagocytosis Assay 
The Phagocytosis Assay Kit (IgG FITC) (Cayman Chemical) was used to 
evaluate the phagocytic capacity. Cells were harvested and resuspended at a 
concentration of 1 × 106cells/ml. The latex beads-rabbit IgG-FITC complex was 
directly added to the cell suspension at a final dilution of 1:200. Cells were 
subsequently cultured at 37C for indicated periods of time. Before measuring the 
fluorescent signal on a flow cytometer, cells were briefly resuspended in trypan blue 
for 5 minutes to quench the surface signal, in order to distinguish the internalized beads 
from surface bound beads. 
2.9 Flow cytometry 
All antibodies for flow cytometry were procured from Biolegend. The panel 
consisted of CD36-FITC (336204), CD8-APC/Cy7 (344714), Ki67-PE (1512109), IFNγ-
BV650 (502538), perforin -PE/Cy7 (353316), granzyme B-APC (372204), HLA-DR-
BV421 (307636), CD80-BV510 (305233), CD83-BV785 (305338), and CD86-BV650 
(105035). For surface markers, cells were treated with TruStain FcXTM (Biolegend, 
422301) as instructed by the manufacturer before staining with antibodies at a dilution 
of 1:100 for 15 minutes at room temperature. Stained cells were subsequently washed 
three times with ice-cold PBS supplemented with 1%FBS before acquiring data by 
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flow-cytometry. For intracellular staining, cells were treated with Brefeldin A (Life 
Technology) to block the secretion of cytokines for 18 hours. The Intracellular Fixation 
and Permeabilization Buffer Set (Invitrogen) was used for intracellular antibody 
staining according to manufacturer’s instructions. Antibodies against intracellular 
targets were used at 1:50 dilution. All FACS data was acquired using Novocyte flow 
cytometer and analyzed using FlowJo software (Tree Star).  
2.10 Statistics 
Data analysis was performed using GraphPad Prism 8 (GraphPad Software 
Inc). Data were presented as mean  s.e.m. Statistical tests were considered 
significant if P-values were  0.05 
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Chapter 3: Results 
3.1 Expression of QKI-5 and PPARδ in dendritic cells 
First, to validate the expression of QKI-5 and PPARδ complex in human 
monocyte derived dendritic cells (moDCs), immunoblotting against QKI-5 was 
performed to detect protein levels of QKI-5 and PPARδ. Generation of moDC started 
with peripheral monocytes, which were cultured in medium containing GM-CSF and 
IL-4 for 6 days to induce their differentiation to immature DCs. Maturation of iDCs can 
be stimulated by various PAMPs or DAMPs, commonly used are TNFα in combination 
with IL-1β, or LPS alone. QKI-5 protein was not detectable in freshly isolated 
monocytes. However, its expression was detectable as early as 2 days after 
differentiation into iDCs and increased till day 4 and then remained stable till day 6, 
suggesting QKI-5 plays a specific role in moDCs. Mature DCs (mDCs), either TNFα 
induced or LPS induced, also expressed QKI-5 at a similar level to the Day 4 and Day 
6 iDCs. The protein expression of PPARδ showed the same trend as QKI-5. However, 
RXRα, a common heterodimerization partner of PPARδ was expressed at very low 


















Figure 1 | QKI5 and PPARδ were upregulated upon monocyte differentiation. 
CD14+CD16- monocytes isolated from peripheral blood were cultured in AIM-V 
medium containing 800 IU/ml of GM-CSF and 500 IU/ml of IL-4 for indicated periods 
of time. Mature DCs were cultured for 6 days and then stimulated with either 10 ng/ml 
of TNFα or 100 ng/ml of LPS for an additional 24 hours. Cells were lysed using RIPA 
lysis buffer supplemented with protease inhibitor. Protein levels were measured by 
immunoblotting. D2, day 2; D4, day 4; D6, day6; iDC, immature DC; mDC, mature DC. 
  
PPARδ 
Figure 2: QKI5 and PPARδ were upregulated upon monocyte differentiation 
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Next the association of QKI-5 is with PPARδ in the moDCs was determined. 
PPAPδ was immunoprecipitated from iDCs. QKI-5 antibody and IgG were used as 
positive and negative controls, respectively. QKI-5 was detected in the QKI-5- and 
PPARδ- but not rabbit IgG-immunoprecipitated aggregates, indicating the association 
of QKI-5 and PPARδ in moDCs (Fig 3). Together, these data suggested a potential 















Figure 2 | QKI5 and PPARδ were associated in iDCs.  
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Cells were cross-linked and then neutralized before 
protein isolation. QKI-5, PPARδ, and IgG were immunoprecipitated using protein G 
beads. Rabbit IgG antibody was included as negative control. The immunoprecipitated 
proteins were then subjected to immunoblot for QKI-5 expression. IP, 
immunoprecipitation; IB, immunoblotting; SE, short exposure; LE, long exposure. 
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3.2 Effect of PPARδ agonist on phagocytosis by dendritic cells 
To investigate the role of QKI-5/PPARδ complex in antigen uptake and cross-
presentation. PPARδ specific agonist, GW501516, was used to enhance the function 
of the QKI-5/PPARδ complex. The optimal drug treatment scheme was determined 
based on the surface expression of the scavenger receptor CD36, a common target of 
QKI-5 and PPARδ. Adding GW501516 on the day when monocytes were plated 
enhanced the surface expression of CD36 to the maximum. Treatment of the cells for 
48 hours resulted in a very small increase in CD36 (Fig 4). In addition, GW501516 did 
not enhance the CD36 surface level in mDCs. This was expected since DCs are known 
to suppress the antigen uptake machinery when matured. It is also worth noting an 
increase in the concentrations of GW501516 for treatment of the cells did not lead to 
a further increase in the expression of CD36, suggesting it was saturated at 100nM. 
GW501516 also increased the mRNA expression levels of other QKI-5 and PPARδ 
common targets, namely Cpt1a and Pdk4, in iDCs generated from three healthy donors 
(Fig 5), suggesting GW501516 is able to enhance the function of QKI-5/PPARδ 
complex.  
To test if enhancing the function of QKI-5/PPARδ complex affects the 
differentiation of moDCs, CD14 and CD209 expressions were assessed by flow 
cytometry. Monocytes express high levels of CD14, which is significantly reduced upon 
differentiation to moDCs. CD209 is a moDC-specific marker and is drastically 
upregulated in response to IL-4 during moDC differentiation (Sander et al., 2017). 
When monocytes were cultured in presence of GM-CSF and IL-4, CD14 expression 
were reduced to the same levels in different concentrations of GW501516-treated and 
vehicle-treated cells. Similarly, CD209 increased to the same extent regardless of the 
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treatments that cells received (Fig 6). Furthermore, the differentiation efficiency (i.e. 
number of moDCs harvested/the number of monocytes plated) did not differ between 
GW501516-treated or untreated cells. In sum, PPARδ agonist does not the affect the 










Figure 3 | GW501516 enhanced CD36 expression in iDCs.  
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Mature DCs were stimulated with 100 ng/ml of LPS 
for an additional 48 hours. iDCs or mDCs were treated with GW501516 at indicated 
concentrations for 7 days (top) or 2 days (bottom). Cell surface expression of CD36 
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Figure 5: GW501516 upregulated QKI5 targets in iDCs 
Immature DCs were generated as previously described. PPARδ agonist, GW501516 
was added on day 0 of the cell culture at indicated concentrations. Expression levels 
of QKI-5 targeting genes, Pdk4 and Cpt1a, were analyzed via quantitative real-time 
PCR. Relative expression to untreated samples is plotted here. RPL13A was used a 
housekeeping gene for normalization. Data represent results from 3 healthy donors. n 
= 2. P values were calculated using two-way ANOVA and adjusted for multiple 
comparison using the Benjamini, Krieger and Yekutieli FDR correction; ns, not 





Figure 6: GW501516 did not affect the differentiation of moDCs 
Monocytes were isolated from human PBMCs. Immature DCs were generated as 
previously described. PPARδ agonist, GW501516 was added on day 0 of the cell 
culture at indicated concentrations. Cell surface expression of CD14 (Left) and CD209 





Next, the effect of GW501516 on the phagocytosis by moDCs was evaluated 
using fluorescent labeled latex beads. When the beads were added to the DC culture, 
the magnitude of the fluorescent signal emitted by DCs indicated the quantity of beads 
that were internalized by the DCs, reflecting their phagocytic capacity. In DCs 
generated from three healthy donors, GW501516 increased the phagocytic capacity of 
iDCs to various degree at 48 hours (Fig 7). Again, mDCs were expected to exhibit low 
phagocytic activity. Surprisingly, GW501516 was able to enhance phagocytosis by 
mDCs in one donor but not the other two, suggesting that in this particular sample, the 








Figure 5 | PPARδ agonist enhanced phagocytosis capacity of iDC.  
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Mature DCs were stimulated with 100 ng/ml of LPS 
for an additional 24 hours. DCs were harvested and incubated with latex Beads-Rabbit 
IgG-FITC complex at 200:1 (v/v) ratio for 48 hours. Cells were briefly incubated with 
trypan blue to quench cell surface staining after incubation. The fluorescent signal 
emitted by internalized beads was assessed by flow cytometry. Results from three 
healthy donors are shown here. Data are presented as mean  s.e.m. P values were 
calculated using two-way ANOVA with Turkey’s multiple comparisons test. P value is 
not significant unless otherwise indicated. Relative MFI was calculated as MFI value 
of treated sample divided by untreated sample. MFI, mean fluorescent intensity; *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
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3.3 Effect of siRNA silencing QKI-5 or PPARδ on phagocytosis by dendritic 
cells 
Ideally, GW501516 should boost the function of the QKI-5/PPARδ complex. 
However, it is still possible any effect that the drug may have on DCs can be attribute 
to PPARδ alone, especially when used at high concentration. To corroborate the role 
of QKI-5 in phagocytosis, individual siRNAs targeting QKI-5 or PPARδ were used to 
suppress their expressions in iDCs and phagocytic activity was evaluated. siRNAs 
targeting QKI reduced around 30% to 40% of the QKI mRNA and reduced QKI-5 
protein expression to a lesser extent (Fig 8). Similarly, siRNAs targeting PPARδ 
reduced around 50% abundance of PPARδ mRNA and decreased the protein 
expression to various degrees. Interestingly, targeting PPARδ downregulated the QKI 
mRNA abundance but not vice versa. Moreover, targeting either QKI or PPARδ 
decreased the protein expressions of both to various extent (Fig 8). Nevertheless, the 
phagocytosis activity was decreased in iDCs to different degrees at 48 hours with 
siPPARδs conferring the highest suppression (Fig 9). These data strongly suggested 





























Figure 6 | siRNA silencing QKI-5 or PPARδ in iDCs.  
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Two different siRNAs targeting QKI-5 or PPARδ 
were tranfected to iDCs at concentration of 50nM using the N-TER transfection reagent 
on first day of iDC generation. Negative siRNA control was used to distinguish specific 
and non-specific targeting. Culture media containing siRNA were removed 24 hours 
post transfection and replenished with fresh media. Cells were harvest for quantitative 
RT-PCR (top) and immunoblotting (bottom) to evaluate the effect of silencing. RPL13A 
was used as housekeeping gene for normalization in RT-qPCR. Vinculin was 
immunoblotted as a loading control. Band intensity was measured by ImageJ to 


















































































Figure 9: Knocking down QKI-5 or PPARδ impaired phagocytosis capacity of 
iDC.  
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Two different siRNAs targeting QKI-5 or PPARδ 
were tranfected to iDCs at concentration of 50nM using the N-TER transfection reagent 
on first day of iDC generation. Negative siRNA control was used to distinguish specific 
and non-specific targeting. Culture media containing siRNA were removed 24 hours 
post transfection and replenished with fresh media. Cells were harvested and 
incubated with latex Beads-Rabbit IgG-FITC complex at 200:1 (v/v) ratio for 48 hours. 
Cells were briefly incubated with trypan blue to quench cell surface staining after 
incubation. The fluorescent signal emitted by internalized beads was assessed by flow 
cytometry. n = 3. Data are presented as mean  s.e.m. P values were calculated using 
ordinary one-way ANOVA with Dunnett’s comparisons test against the control group. 
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Relative MFI was calculated as MFI value of treated sample divided by untreated 
sample. P value is not significant unless otherwise indicated. siControl, siRNA negative 
control; MFI, mean fluorescent intensity;  ***P ≤ 0.001, ****P ≤ 0.0001. 
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3.4 Effect of PPARδ agonist on antigen cross-presentation by dendritic cells 
To test whether the increase in phagocytic capacity by GW501516 enhances 
the antigen cross-presentation by DCs, several approaches were employed.  
First, DCs were treated with 12.5 μg/ml of whole MART-1 protein one day before 
they were matured using LPS (Fig 10). Once the protein got internalized and cross-
presented, these mDCs should be able to re-stimulate HLA-matched antigen-specific 
CTLs, i.e. M27 CTLs. M27 peptide pulsed-DCs were used as positive control while NY-
ESO peptide pulsed-DCs and un-pulsed DCs were used as negative controls (Fig 10). 
The capacity of DC-induced T cell response was measured as T cell proliferation and 
effector cytokine production. M27 CTLs co-cultured with whole MART-1 protein-
fedDCs were not activated as they showed no increase in IFNγ, perforin A and Ki67 
stainings compared to negative controls, regardless whether they were GW501516 





Figure 10: Experimental scheme for MART-1 whole protein cross-presentation 
assay 
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described with either GW501516 or vehicle control treatments 
on the first day of DC generation. On Day 5, the testing group was treated with 12.5 
μg/ml of MART-1 whole protein. On Day 6, DCs were matured with LPS at 
concentration of 100 ng/ml before they were co-cultured with M27 CTL at 1:10 ratio. 
The positive control group was pulsed with 40 μg/ml of M27 peptide. Cells in negative 
control group were either pulsed with 40 μg/ml of NY-ESO peptide or had no antigen 
exposure. Two days post DC/T cell co-culture, cells were harvested for assessment 






Figure 11: DCs fed with MART-1 whole protein failed to elicit M27 CTL response 
M27 CTLs co-cultured with MART-1 whole protein fed DCs were harvested. Brefeldin 
A was used to block the cytokine secretion 18 hours before cells were harvested. Cells 
were washed and treated with permeabilization solution before stained with CD8-
APC/Cy7, Ki67-PE, perforin-PE/Cy7, IFNγ-BV650 and Live/Dead Aqua. Stained cells 
were assessed by flow cytometry. The expression analysis of indicated proteins were 
gated on CD8+ viable cells. The percentages of cells that were positive for indicated 
proteins are shown here. n = 3. Data are presented as mean  s.e.m. P values were 
calculated using two-way ANOVA with Turkey’s multiple comparisons test. P value is 
not significant unless otherwise indicated. 
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Second approach involved treatment of DCs with irradiated tumor cells with high 
MART-1 protein expression (A2058 cell line). The tumor cell lysate was present in the 
DC culture media for 2 or 5 days before DCs were matured and harvested (Fig 12). 
Again, these DCs were subsequently co-cultured with HLA-matched M27 CTLs. The 
T cell response was measured as effector cytokine production. DCs that were not fed 
with cell lysate were used as negative control and non-fed DCs pulsed with M27 
peptides were used as positive control. In addition, M27 CTLs could be directly 
activated by the HLA-matched, MART-1 expressing tumor cells (Mel526), but not 
A2058 cells since they were HLA-mismatched (Fig 13). DCs co-cultured with MART-1 
expressing tumor cell lysate failed to simulate M27 CTLs as shown by granzyme b (Fig 
13, top) and IFNγ secretion (Fig 13, bottom), regardless of how long the cell lysate was 
present in the DC culture and regardless of whether DCs were treated with GW501516. 
Further investigation on these DCs revealed that their co-stimulatory molecule CD80, 
CD86 and CD83 are drastically decreased if they were fed with tumor cell lysate (Fig 





Figure 12: Experimental scheme for A2058 cell cross-presentation assay 
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described with either 500nM GW501516 or vehicle control 
treatments on the first day of DC generation. On Day 2 or 5, the testing groups were 
added irradiated A2058 cells at 1:10 ratio (DC:A2058). On Day 6, DCs were matured 
with LPS at concentration of 100 ng/ml before they were co-cultured with M27 CTL at 
1:10 ratio. The positive control group was not treated with A2058 cell lysate and pulsed 
with 40 μg/ml of M27 peptide. Cells in negative control group were either pulsed with 
40 μg/ml of NY-ESO peptide or had no antigen exposure. Two days post DC/T cell co-











Figure 13: DCs fed with A2058 cell lysate failed to elicit M27 CTL response 
M27 CTLs co-cultured with A2058 cell lysate fed DCs were harvested. Brefeldin A was 
used to block the cytokine secretion 18 hours before cells were harvested. Cells were 
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granzyme b-APC and Live/Dead Aqua. Stained cells were assessed by flow cytometry. 
The expression analysis of indicated proteins were gated on CD8+ viable cells. Before 
bredfeldin A was added, cell culture supernatants were harvested and use for ELISA 
analysis to detect IFNγ secretion. MFI, mean fluorescent intensity. n = 2. Data are 





Figure 14: Expressions of co-stimulatory molecules by DCs were downregulated 
upon A2058 cell lysate exposure 
A2058 cell lysate fed-DCs were generated as previously described. DCs were 
harvested for flow cytometry before M27 CTL co-culturing in order to assess the 
expression of co-stimulatory molecules. Cells were washed and stained with HLA-DR-
BV421, CD80-BV510, CD83-BV785, and CD86-BV650 antibodies. Cells were gated 




A third method to test antigen cross-presentation was the PR1 cross-
presentation assay. PR1 is a leukemia-associated, HLA-A2-restricted peptide derived 
from neutrophil elastase and protease 3, which are found abundantly in 
polymorphonuclear neutrophils (PMN) (Reiter et al., 1997). The 8F4 antibody 
specifically recognizes PR1-bound HLA-A2 conformational epitope (Sergeeva et al., 
2016), which can therefore be used to directly measure the PR1/HLA-A2 presented on 
DC surface. PMN freeze-thaw lysate was used as source of antigen to feed DCs for 
different periods of time and the cross-presentation was evaluated by flow cytometry 
using the 8F4 antibody. Two different feeding schemes were used. First, PMN lysate 
was added to the DC culture on the day 4 of monocyte differentiation process while 
DCs were at the immature stage (Fig 15). iDCs were harvested on Day 5 or Day 6 
when they have been exposed to PMN lysate for 24 or 48 hours, respectively. Another 
group of PMN lysate fed cells were matured by LPS on Day 6 and harvested 1- or 2-
days post maturation. They had been exposed to PMN lysate for 72 or 96 hours. PR1 
peptide pulsed or unpulsed iDCs and mDCs were used as control. Peptide pulsed cells 
showed higher 8F4 stainings in both iDCs and mDCs (Fig 16), indicating 8F4 as a 
reliable marker to test the cross-presented PR1/HLA-A2. Matured DCs presented more 
PR1 than iDCs in a time-dependent manner (Fig 17), as maturation generally promotes 
the expression of MHC molecules. However, regardless of how long that DCs were 
exposed to PMN lysate, GW501516 treated iDCs and mDCs did not show higher 8F4 





Figure 15: Experimental scheme 1 for PR1 cross-presentation assay 
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described with either 500nM GW501516 or vehicle control 
treatments on the first day of DC generation. On Day 4, PMN lysate was added to the 
cell culture at 3:1 ratio (i.e. 3 PMNs to 1 DC). Cells in group 1 and group 2 were 
harvested for 8F4 staining and flow cytometry analysis 24 or 48 hour later, respectively. 
Another two groups of DCs were matured on day 6 using 100 ng/ml of LPS and 





Figure 16: The 8F4 staining on PR1 peptide pulsed or unpulsed DCs 
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Maturation was induced using 100 ng/ml of LPS on 
day 6. Matured DCs were harvested 24 hours after. Both iDCs and mDCs were 
subjected to 8F4 staining and assessed by flow cytometry. DCs were gated on CD209+ 






Figure 17: The 8F4 staining on PMN lysate fed DCs 
Immature and mature DCs exposed to PMN lysate following the feeding scheme 1 
were harvested and subjected to 8F4 staining and assessed by flow cytometry. DCs 
were gated on CD209+ and CD62L- population. Histograms of 8F4 expression (top) 
and bar graphs of MFI (bottom) are shown here. FMO, fluorescent minus one; MFI, 
mean fluorescent intensity; PMN, polymorphonuclear neutrophils. 
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In the second scheme, iDCs and mDCs were generated without exposure to the 
PMN lysate. After iDCs and mDCs were harvested on Day 7, they were counted and 
re-plated with PMN cell lysate following incubation for indicated periods of time (Fig 
18). The 8F4 staining, which reflected the expression of PR1/HLA-A2 on the cell 
surface, showed no significant difference between DCs treated with vehicle control or 






Figure 18: Experimental scheme 2 for PR1 cross-presentation assay 
Immature DCs and mature DCs were generated from CD14+CD16- monocytes using 
GM-CSF and IL-4 for 7 days as previously described with either 500nM GW501516 or 
vehicle control treatments on the first day of DC generation. LPS was used to mature 
the cells at concentration of 100 ng/ml. Cells were harvested on day 7 and co-cultured 
with PMN cell lysate at 1:3 ratio (1 DC to 3 PMNs). The DC/PMN mixtures were 
incubated for extra 4 days and assessed for PR1/HLA-A2 expression at different time 





Figure 19: The 8F4 staining on PMN lysate fed DCs 
Immature and mature DCs exposed to PMN lysate according the feeding scheme 2 
were harvested and subjected to 8F4 staining and assessed by flow cytometry. DCs 
were gated on CD209+ and CD62L- population. n = 3. Data are presented as mean  
s.e.m. P values were calculated using two-way ANOVA with Turkey’s multiple 
comparisons test. MFI, mean fluorescent intensity; ns, not significant. 
 
  

































Chapter 4: Discussion 
The work presented here sheds light on the regulation of antigen uptake and 
cross-presentation by human dendritic cells. It demonstrates here a previously 
unknown/novel function of an RNA-binding protein, QKI as a positive regulator of 
phagocytosis by DCs. In addition, the previously proposed function of QKI-5/PPARδ 
complex that QKI-5 can function independently of its RNA-binding activity was 
validated in the human primary DCs. This study showed that QKI-5 can act as a co-
activator for the nuclear receptor PPARδ and enhance the downstream gene activation 
in human DCs. However, the most common heterodimerization partner of PPARδ, 
RXRα was expressed in iDCs at very low level, not comparable to the PPARδ 
expression and not present in mDCs. This suggests that previously discovered QKI-
5/PPARδ/RXRα interaction is cell type dependent and there may be other nuclear 
receptors forming heterodimers with PPARδ and could be co-activated by QKI-5. 
In addition, the co-immunoprecipitation of PPARδ revealed that only a fraction 
of QKI-5 was associated with PPARδ, indicating QKI-5 also has other functions 
independent of the QKI-5/PPARδ complex. However, we demonstrated here that 
enhancing PPARδ function by GW501516 increased the phagocytosis by DCs while 
silencing PPARδ or QKI-5 showed the opposite effect. These data strongly suggest 
the role of the QKI-5/PPARδ complex in regulating the phagocytosis by iDCs. Although 
the mechanism was not investigated in this study, it is possible that the upregulation 
phagosome/endosome signaling by QKI results in the enhanced phagocytosis.  
Once DCs become mature, they are considered to transcriptionally slow down 
the antigen uptake machinery and switch to antigen presentation. In one sample, 
GW501516 enhanced the beads uptake by iDCs and this effect persisted even after 
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the cells had matured, indicating that GW501516 can help in overcoming the 
transcriptional suppression of antigen uptake. However, this was only observed in one 
out of three samples. This donor variation could be explained by the existence of single 
nucleotide polymorphism in close proximity to qk gene, which was shown to affect the 
function of QKI-5 in myocardial tissue (Dehghan et al., 2016). This postulation needs 
to be further investigated on a larger number of samples before arriving at a firm 
conclusion.  
It has been demonstrated monocytes from QKI-haploinsufficient atherosclerotic 
patients have reduced capacity to differentiate under M-CSF or GM-CSF (De Bruin et 
al., 2016). However, our experiments manipulating QKI-5/PPARδ function (either by 
siRNA silencing or by agonist treatment) did not affect DC morphology or the number 
of DC generated from a fixed number of monocytes (data not shown), suggesting no 
significant impairment of monocyte differentiation was observed in our experimental 
system. The discrepancy between two studies can be explained by the fact that there 
other confounding factors that affect monocyte differentiation maybe present in 
atherosclerotic patient sample and were absent in healthy donor samples that we used. 
Moreover, we used GM-CSF in combination with IL-4 to induce monocyte 
differentiation where IL-4 is specifically used to create the inflammatory phenotype. 
The differences in the experimental systems made comparison of the two studies 
difficult. Yet, both studies indicated the importance of QKI in monocyte-
macrophage/monocyte-DC axis.  
Our study tried to assess cross-presentation by GW501516-treated DCs. Using 
tumor antigens and established CTL lines, the capability of DCs to activate T cells was 
evaluated by effector cytokine production by T cells. However, this approach was not 
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a direct measurement of DC cross-presentation. The capability of DCs to activate T 
cells cannot fully represent the amount of pMHC present on the DC surface since it 
can also be affected by other factors such as co-stimulatory molecules and cytokines 
presented or secreted by DCs. Indeed, we found tumor cell lysate fed-DCs failed to 
induce T cell response, regardless whether they were GW501516 treated or not, 
suggesting this experimental approach was not optimal. Furthermore, co-stimulatory 
molecules (CD80, CD86, and CD83) were significantly downregulated in tumor cell 
lysate fed DCs, which partially explained why CTLs were not activated.  
The monoclonal antibody 8F4 has been used in several studies and clinical trials 
where their strong and specific binding to PR1-A2 conformational epitope have been 
demonstrated. Therefore, it is considered a reliable and direct measurement of DC 
cross-presentation. In our PR1 cross-presentation experiment, there was no increase 
in 8F4 staining in GW501516-treated DCs as compared to vehicle control, indicating 
they cross-presented similar level of PR-1 peptide. Therefore, it can be concluded that 
GW501516 does not enhance DC cross-presentation. The QKI-5/PPARδ may not 
directly regulate antigen cross-presentation by DC.  
Our initial hypothesis assumed that enhanced antigen uptake will lead to 
increased antigen cross-presentation, i.e. more the cells ingest, greater will be the 
antigen presentation. However, the study led to the recognition that cellular regulation 
of cross-presentation is a highly complex phenomenon involving several different 
pathways and our approach was limited in addressing that complexity. Enhancing 
phagocytosis by QKI-5, likely due to its regulation on endosome/phagosome signaling, 
does not necessarily improve cross-presentation as shown by our data.  
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Instead, antigen cross-presentation is a complex process that requires the 
coordination among endosome/phagosome signaling, lysosomal acidification, 
cytosolic proteases. After antigen being taken up and forming early 
endosomes/phagosomes, the antigen-containing vesicles need to go through a serial 
step of maturation and trafficking before reaching to the final cross-presenting 
organelle. Two major pathways where antigens are processed have been proposed 
(Fig 1). In the vacuolar pathway, antigens remain in the endosomal compartment. Their 
encounter with proteases and empty MHC Class I molecules is achieved by fusing with 
proteases-containing lysosomes and MHC Class I-containing recycling endosomes. 
Antigens processed in the cytosolic pathways require extensive transportation in and 
out of different endosomal and ER compartments.  Each step is precisely controlled in 
DC to generate and preserve immunogenic peptides for cross-presentation. For 
example, Rab27a induces the fusion of NOX2-containing lysosomes to antigen-
containing compartments. Rab11a and Rab22a maintain the intracellular pool of MHC 
class I molecules. Silencing these proteins does not affect antigen uptake but impairs 
cross-presentation. Modulating antigen uptake alone may not perturb the following 
antigen processing and cross-presenting steps. There may exist other mechanisms 
regulating each step involved in antigen-presentation so that this first event in adaptive 








































Supplementary Figure 1: PPARδ enhanced the phagocytic capacity of iDC 
 Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-
4 for 6 days as previously described. Mature DCs were stimulated with 100 ng/ml of 
LPS for an additional 24 hours. DCs were harvested and incubated with latex Beads-
Rabbit IgG-FITC complex at 200:1 (v/v) ratio for indicated periods of time. Cells were 
briefly incubated with trypan blue to quench cell surface staining after incubation. The 
fluorescent signal emitted by internalized beads was assessed by flow cytometry. 
Results from three healthy donors (Top, Middle, and Bottom) are shown here. Data 




Supplementary Figure 2: Knocking down QKI-5 or PPARδ impaired 
phagocytosis capacity of iDC. 
Immature DCs were generated from CD14+CD16- monocytes using GM-CSF and IL-4 
for 6 days as previously described. Two different siRNAs targeting QKI-5 or PPARδ 
were tranfected to iDCs at concentration of 50nM using the N-TER transfection reagent 
on first day of iDC generation. Negative siRNA control was used to distinguish specific 
and non-specific targeting. Culture media containing siRNA were removed 24 hours 
post transfection and replenished with fresh media. Cells were harvested and 
incubated with latex Beads-Rabbit IgG-FITC complex at 200:1 (v/v) ratio for indicated 
periods of time. Cells were briefly incubated with trypan blue to quench cell surface 
staining after incubation. The fluorescent signal emitted by internalized beads was 
assessed by flow cytometry. n = 3. Data are presented as mean  s.e.m. siControl, 





Åberg, K., Saetre, P., Jareborg, N., & Jazin, E. (2006). Human QKI, a potential 
regulator of mRNA expression of human oligodendrocyte-related genes involved 
in schizophrenia. Proceedings of the National Academy of Sciences of the 
United States of America, 103(19), 7482–7487. 
https://doi.org/10.1073/pnas.0601213103 
Abram, C. L., & Lowell, C. A. (2009). The Ins and Outs of Leukocyte Integrin 
Signaling. Annual Review of Immunology, 27(1), 339–362. 
https://doi.org/10.1146/annurev.immunol.021908.132554 
Ackerman, A. L., Giodini, A., & Cresswell, P. (2006). A Role for the Endoplasmic 
Reticulum Protein Retrotranslocation Machinery during Crosspresentation by 
Dendritic Cells. Immunity, 25(4), 607–617. 
https://doi.org/10.1016/j.immuni.2006.08.017 
Adhikary, T., Wortmann, A., Schumann, T., Finkernagel, F., Lieber, S., Roth, K., 
Toth, P. M., Diederich, W. E., Nist, A., Stiewe, T., Kleinesudeik, L., Reinartz, S., 
Müller-Brüsselbach, S., & Müller, R. (2015). The transcriptional PPARβ/δ 
network in human macrophages defines a unique agonist-induced activation 
state. Nucleic Acids Research, 43(10), 5033–5051. 
https://doi.org/10.1093/nar/gkv331 
Autenrieth, S. E., & Autenrieth, I. B. (2009). Variable antigen uptake due to different 
expression of the macrophage mannose receptor by dendritic cells in various 
inbred mouse strains. Immunology, 127(4), 523–529. 
https://doi.org/10.1111/j.1365-2567.2008.02960.x 
Bertram, E. M., Hawley, R. G., & Watts, T. H. (2002). Overexpression of rab7 
 63 
enhances the kinetics of antigen processing and presentation with MHC class II 
molecules in B cells. International Immunology, 14(3), 309–318. 
https://doi.org/10.1093/intimm/14.3.309 
Biologie, B. De, & Cellulaire, D. B. (1996). Differential expression of peroxisom 
proliferatior activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -
γ in the adult rat. Proceedings of the National Academy of Sciences, 137(1), 
354–366. 
Cai, L., Marshall, T. W., Uetrecht, A. C., Schafer, D. A., & Bear, J. E. (2007). Coronin 
1B Coordinates Arp2/3 Complex and Cofilin Activities at the Leading Edge. Cell, 
128(5), 915–929. https://doi.org/10.1016/j.cell.2007.01.031 
Canton, J. (2018). Macropinocytosis: New insights into its underappreciated role in 
innate immune cell surveillance. Frontiers in Immunology, 9(OCT), 1–8. 
https://doi.org/10.3389/fimmu.2018.02286 
Canton, J., Schlam, D., Breuer, C., Gütschow, M., Glogauer, M., & Grinstein, S. 
(2016). Calcium-sensing receptors signal constitutive macropinocytosis and 
facilitate the uptake of NOD2 ligands in macrophages. Nature Communications, 
7. https://doi.org/10.1038/ncomms11284 
Darbelli, L., & Richard, S. (2016). Emerging functions of the Quaking RNA-binding 
proteins and link to human diseases. Wiley Interdisciplinary Reviews: RNA, 7(3), 
399–412. https://doi.org/10.1002/wrna.1344 
De Bruin, R. G., Shiue, L., Prins, J., De Boer, H. C., Singh, A., Fagg, W. S., Van Gils, 
J. M., Duijs, J. M. G. J., Katzman, S., Kraaijeveld, A. O., Böhringer, S., Leung, 
W. Y., Kielbasa, S. M., Donahue, J. P., Van Der Zande, P. H. J., Sijbom, R., Van 
Alem, C. M. A., Bot, I., Van Kooten, C., … Van Der Veer, E. P. (2016). Quaking 
 64 
promotes monocyte differentiation into pro-atherogenic macrophages by 
controlling pre-mRNA splicing and gene expression. Nature Communications, 
7(2). https://doi.org/10.1038/ncomms10846 
Dehghan, A., Bis, J. C., White, C. C., Smith, A. V., Morrison, A. C., Cupples, L. A., 
Trompet, S., Chasman, D. I., Lumley, T., Volker, U., Buckley, B. M., Ding, J., 
Jensen, M. K., Folsom, A. R., Kritchevsky, S. B., Girman, C. J., Ford, I., Dorr, M., 
Salomaa, V., … O’Donnell, C. J. (2016). Genome-Wide Association Study for 
Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort 
Studies: The CHARGE Consortium. PLoS ONE, 11(3), 1–16. 
https://doi.org/10.1371/journal.pone.0144997 
Delamarre, L., Pack, M., Chang, H., Mellman, I., & Trombetta, E. S. (2005). 
Differential lysosomal proteolysis in antigen-presenting cells determines antigen 
fate. Science, 307(5715), 1630–1634. https://doi.org/10.1126/science.1108003 
Dingjan, I., Verboogen, D. R. J., Paardekooper, L. M., Revelo, N. H., Sittig, S. P., 
Visser, L. J., Von Mollard, G. F., Henriet, S. S. V., Figdor, C. G., Ter Beest, M., & 
Van Den Bogaart, G. (2016). Lipid peroxidation causes endosomal antigen 
release for cross-presentation. Scientific Reports, 6(July 2015), 1–12. 
https://doi.org/10.1038/srep22064 
Dunn, S. E., Bhat, R., Straus, D. S., Sobel, R. A., Axtell, R., Johnson, A., Nguyen, K., 
Mukundan, L., Moshkova, M., Dugas, J. C., Chawla, A., & Steinman, L. (2010). 
Peroxisome proliferator-activated receptor δ limits the expansion of pathogenic 
Th cells during central nervous system autoimmunity. Journal of Experimental 
Medicine, 207(8), 1599–1608. https://doi.org/10.1084/jem.20091663 
Egami, Y., Taguchi, T., Maekawa, M., Arai, H., & Araki, N. (2014). Small GTPases 
 65 
and phosphoinositides in the regulatory mechanisms of macropinosome 
formation and maturation: Gtpases and phosphoinositides in macropinocytosis. 
Frontiers in Physiology, 5(SEP), 1–11. https://doi.org/10.3389/fphys.2014.00374 
Freeman, S. A., & Grinstein, S. (2014). Phagocytosis: Receptors, signal integration, 
and the cytoskeleton. Immunological Reviews, 262(1), 193–215. 
https://doi.org/10.1111/imr.12212 
Griffin, J. P., Chu, R., & Harding, C. V. (1997). Early endosomes and a late endocytic 
compartment generate different peptide-class II MHC complexes via distinct 
processing mechanisms. Journal of Immunology (Baltimore, Md. : 1950), 158(4), 
1523–1532. http://www.ncbi.nlm.nih.gov/pubmed/9029086 
Halenius, A., Gerke, C., & Hengel, H. (2015). Classical and non-classical MHC i 
molecule manipulation by human cytomegalovirus: So many targets - But how 
many arrows in the quiver? Cellular and Molecular Immunology, 12(2), 139–153. 
https://doi.org/10.1038/cmi.2014.105 
Hardy, R. J. (1998). Molecular defects in the dysmyelinating mutant quaking. Journal 
of Neuroscience Research, 51(4), 417–422. https://doi.org/10.1002/(SICI)1097-
4547(19980215)51:4<417::AID-JNR1>3.0.CO;2-F 
Höning, S., Ricotta, D., Krauss, M., Späte, K., Spolaore, B., Motley, A., Robinson, M., 
Robinson, C., Haucke, V., & Owen, D. J. (2005). Phosphatidylinositol-(4,5)-
bisphosphate regulates sorting signal recognition by the clathrin-associated 
adaptor complex AP2. Molecular Cell, 18(5), 519–531. 
https://doi.org/10.1016/j.molcel.2005.04.019 
Jancic, C., Savina, A., Wasmeier, C., Tolmachova, T., El-Benna, J., Dang, P. M. C., 
Pascolo, S., Gougerot-Pocidalo, M. A., Raposo, G., Seabra, M. C., & Amigorena, 
 66 
S. (2007). Rab27a regulates phagosomal pH and NADPH oxidase recruitment to 
dendritic cell phagosomes. Nature Cell Biology, 9(4), 367–378. 
https://doi.org/10.1038/ncb1552 
Jaqaman, K., Kuwata, H., Touret, N., Collins, R., Trimble, W. S., Danuser, G., & 
Grinstein, S. (2011). Cytoskeletal control of CD36 diffusion promotes its receptor 
and signaling function. Cell, 146(4), 593–606. 
https://doi.org/10.1016/j.cell.2011.06.049 
Jaumouillé, V., Farkash, Y., Jaqaman, K., Das, R., Lowell, C. A., & Grinstein, S. 
(2014). Actin cytoskeleton reorganization by syk regulates fcγ receptor 
responsiveness by increasing its lateral mobility and clustering. Developmental 
Cell, 29(5), 534–546. https://doi.org/10.1016/j.devcel.2014.04.031 
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012). Cross-presentation by 
dendritic cells. Nature Reviews Immunology, 12(8), 557–569. 
https://doi.org/10.1038/nri3254 
Kondo, T., Furuta, T., Mitsunaga, K., Ebersole, T. A., Shichiri, M., Wu, J., Artzt, K., 
Yamamura, K. ichi, & Abe, K. (1999). Genomic organization and expression 
analysis of the mouse qkI locus. Mammalian Genome, 10(7), 662–669. 
https://doi.org/10.1007/s003359901068 
Kosaka, T., & Ikeda, K. (1983). Reversible blockage of membrane retrieval and 
endocytosis in the garland cell of the temperature-sensitive mutant of Drosophila 
melanogaster, shibirets1. The Journal of Cell Biology, 97(2), 499–507. 
https://doi.org/10.1083/jcb.97.2.499 
Liu, Z., & Roche, P. A. (2015). Macropinocytosis in phagocytes: Regulation of MHC 
class-II-restricted antigen presentation in dendritic cells. Frontiers in Physiology, 
 67 
6(JAN), 1–6. https://doi.org/10.3389/fphys.2015.00001 
Marion, S., Mazzolini, J., Herit, F., Bourdoncle, P., Kambou-Pene, N., Hailfinger, S., 
Sachse, M., Ruland, J., Benmerah, A., Echard, A., Thome, M., & Niedergang, F. 
(2012). The NF-κB Signaling Protein Bcl10 Regulates Actin Dynamics by 
Controlling AP1 and OCRL-Bearing Vesicles. Developmental Cell, 23(5), 954–
967. https://doi.org/10.1016/j.devcel.2012.09.021 
Massol, R. H., Boll, W., Griffin, A. M., & Kirchhausen, T. (2006). A burst of auxilin 
recruitment determines the onset of clathrin-coated vesicle uncoating. 
Proceedings of the National Academy of Sciences of the United States of 
America, 103(27), 10265–10270. https://doi.org/10.1073/pnas.0603369103 
McMahon, H. T., & Boucrot, E. (2011). Molecular mechanism and physiological 
functions of clathrin-mediated endocytosis. Nature Reviews Molecular Cell 
Biology, 12(8), 517–533. https://doi.org/10.1038/nrm3151 
Mukundan, L., Odegaard, J. I., Morel, C. R., Heredia, J. E., Mwangi, J. W., Ricardo-
Gonzalez, R. R., Goh, Y. P. S., Eagle, A. R., Dunn, S. E., Awakuni, J. U. H., 
Nguyen, K. D., Steinman, L., Michie, S. A., & Chawla, A. (2009). PPAR-δ senses 
and orchestrates clearance of apoptotic cells to promote tolerance. Nature 
Medicine, 15(11), 1266–1272. https://doi.org/10.1038/nm.2048 
Neefjes, J. (1999). CIIV, MIIC and other compartments for MHC class II loading. 
European Journal of Immunology, 29(5), 1421–1425. 
https://doi.org/10.1002/(SICI)1521-4141(199905)29:05<1421::AID-
IMMU1421>3.0.CO;2-C 
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., 
Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998). Ligand 
 68 
binding and co-activator assembly of the peroxisome proliferator- activated 
receptor-γ. Nature, 395(6698), 137–143. https://doi.org/10.1038/25931 
Noveroske, J. K., Lai, L., Gaussin, V., Northrop, J. L., Nakamura, H., Hirschi, K. K., & 
Justice, M. J. (2002). Quaking is essential for blood vessel development. 
Genesis, 32(3), 218–230. https://doi.org/10.1002/gene.10060 
Park, J., Talukder, A. H., Lim, S. A., Kim, K., Pan, K., Melendez, B., Bradley, S. D., 
Jackson, K. R., Khalili, J. S., Wang, J., Creasy, C., Pan, B. F., Woodman, S. E., 
Bernatchez, C., Hawke, D., Hwu, P., Lee, K. M., Roszik, J., Lizee, G., & Yee, C. 
(2017). SLC45A2: A melanoma antigen with high tumor selectivity and reduced 
potential for autoimmune toxicity. Cancer Immunology Research, 5(8), 618–629. 
https://doi.org/10.1158/2326-6066.CIR-17-0051 
Patel, P. C., & Harrison, R. E. (2008). Membrane Ruffles Capture C3bi-opsonized 
Particles in Activated Macrophages. Molecular Biology of the Cell, 
19(November), 4628–4639. https://doi.org/10.1091/mbc.E08 
Peaper, D. R., Wearsch, P. A., & Cresswell, P. (2005). Tapasin and ERp57 form a 
stable disulfide-linked dimer within the MHC class I peptide-loading complex. 
EMBO Journal, 24(20), 3613–3623. https://doi.org/10.1038/sj.emboj.7600814 
Ravnskjaer, K., Frigerio, F., Boergesen, M., Nielsen, T., Maechler, P., & Mandrup, S. 
(2010). PPARδ is a fatty acid sensor that enhances mitochondrial oxidation in 
insulin-secreting cells and protects against fatty acid-induced dysfunction. 
Journal of Lipid Research, 51(6), 1370–1379. 
https://doi.org/10.1194/jlr.M001123 
Redka, D. S., Gütschow, M., Grinstein, S., & Canton, J. (2018). Differential ability of 
proinflammatory and anti-inflammatory macrophages to perform 
 69 
macropinocytosis. Molecular Biology of the Cell, 29(1), 53–65. 
https://doi.org/10.1091/mbc.E17-06-0419 
Reiter, Y., Di Carlo, A., Fugger, L., Engberg, J., & Pastan, I. (1997). Peptide-specific 
killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein 
targeted to major histocompatibility complex/peptide class I complexes with T 
cell receptor-like specificity. Proceedings of the National Academy of Sciences of 
the United States of America, 94(9), 4631–4636. 
https://doi.org/10.1073/pnas.94.9.4631 
Roche, P. A., & Furuta, K. (2015). The ins and outs of MHC class II-mediated antigen 
processing and presentation. Nature Reviews Immunology, 15(4), 203–216. 
https://doi.org/10.1038/nri3818 
Rohatgi, R., Ma, L., Miki, H., Lopez, M., Kirchhausen, T., Takenawa, T., & Kirschner, 
M. W. (1999). N-WASP activates the Arp2/3 complex and links Cdc42 and 
phosphoinositide signals to actin assembly. Molecular Biology of the Cell, 10(S), 
122A. 
Romanowska, M., Reilly, L., Palmer, C. N. A., Gustafsson, M. C. U., & Foerster, J. 
(2010). Activation of PPARβ/δ causes a psoriasis-like skin disease in vivo. PLoS 
ONE, 5(3). https://doi.org/10.1371/journal.pone.0009701 
Sander, J., Schmidt, S. V., Cirovic, B., McGovern, N., Papantonopoulou, O., Hardt, A. 
L., Aschenbrenner, A. C., Kreer, C., Quast, T., Xu, A. M., Schmidleithner, L. M., 
Theis, H., Thi Huong, L. Do, Sumatoh, H. R. Bin, Lauterbach, M. A. R., Schulte-
Schrepping, J., Günther, P., Xue, J., Baßler, K., … Schultze, J. L. (2017). 
Cellular Differentiation of Human Monocytes Is Regulated by Time-Dependent 
Interleukin-4 Signaling and the Transcriptional Regulator NCOR2. Immunity, 
 70 
47(6), 1051-1066.e12. https://doi.org/10.1016/j.immuni.2017.11.024 
Savina, A., Jancic, C., Hugues, S., Guermonprez, P., Vargas, P., Moura, I. C., 
Lennon-Duménil, A. M., Seabra, M. C., Raposo, G., & Amigorena, S. (2006). 
NOX2 Controls Phagosomal pH to Regulate Antigen Processing during 
Crosspresentation by Dendritic Cells. Cell, 126(1), 205–218. 
https://doi.org/10.1016/j.cell.2006.05.035 
Scholtysek, C., Katzenbeisser, J., Fu, H., Uderhardt, S., Ipseiz, N., Stoll, C., Zaiss, M. 
M., Stock, M., Donhauser, L., Böhm, C., Kleyer, A., Hess, A., Engelke, K., David, 
J. P., Djouad, F., Tuckermann, J. P., Desvergne, B., Schett, G., & Krönke, G. 
(2013). PPARβ/δ governs Wnt signaling and bone turnover. Nature Medicine, 
19(5), 608–613. https://doi.org/10.1038/nm.3146 
Schuette, V., & Burgdorf, S. (2014). The ins-and-outs of endosomal antigens for 
cross-presentation. Current Opinion in Immunology, 26(1), 63–68. 
https://doi.org/10.1016/j.coi.2013.11.001 
Sergeeva, A., He, H., Ruisaard, K., St John, L., Alatrash, G., Clise-Dwyer, K., Li, D., 
Patenia, R., Hong, R., Sukhumalchandra, P., You, M. J., Gagea, M., Ma, Q., & 
Molldrem, J. J. (2016). Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 
antibody, against primary human AML in vivo. Leukemia, 30(7), 1475–1484. 
https://doi.org/10.1038/leu.2016.57 
Shingu, T., Ho, A. L., Yuan, L., Zhou, X., Dai, C., Zheng, S., Wang, Q., Zhong, Y., 
Chang, Q., Horner, J. W., Liebelt, B. D., Yao, Y., Hu, B., Chen, Y., Fuller, G. N., 
Verhaak, R. G. W., Heimberger, A. B., & Hu, J. (2017). Qki deficiency maintains 
stemness of glioma stem cells in suboptimal environment by downregulating 
endolysosomal degradation. Nature Genetics, 49(1), 75–86. 
 71 
https://doi.org/10.1038/ng.3711 
Steinman, R. M., & Cohn, Z. A. (1973). Identification of a novel cell type in peripheral 
lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. Journal 
of Experimental Medicine, 137(5), 1142–1162. 
https://doi.org/10.1084/jem.137.5.1142 
Tuson, H. H., Auer, G. K., Renner, L. D., Hasebe, M., Tropini, C., Salick, M., Crone, 
W. C., Gopinathan, A., Huang, K. C., & Weibel, D. B. (2012). Measuring the 
stiffness of bacterial cells from growth rates in hydrogels of tunable elasticity. 
Molecular Microbiology, 84(5), 874–891. https://doi.org/10.1111/j.1365-
2958.2012.08063.x 
Ullrich, O., Reinsch, S., Urbé, S., Zerial, M., & Parton, R. G. (1996). Rab11 regulates 
recycling through the pericentriolar recycling endosome. Journal of Cell Biology, 
135(4), 913–924. https://doi.org/10.1083/jcb.135.4.913 
Uribe-Quero, E., & Rosales, C. (2017). Control of phagocytosis by microbial 
pathogens. Frontiers in Immunology, 8(OCT), 1–23. 
https://doi.org/10.3389/fimmu.2017.01368 
Wang, L., Zhai, D.-S., Ruan, B.-J., Xu, C.-M., Ye, Z.-C., Lu, H.-Y., Jiang, Y.-H., 
Wang, Z.-Y., Xiang, A., Yang, Y., Yuan, J.-L., & Lu, Z.-F. (2017). Quaking 
Deficiency Amplifies Inflammation in Experimental Endotoxemia via the Aryl 
Hydrocarbon Receptor/Signal Transducer and Activator of Transcription 1-NF-κB 
Pathway. Frontiers in Immunology, 8, 1754. 
https://doi.org/10.3389/fimmu.2017.01754 
Wang, Y. X., Lee, C. H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. 
(2003). Peroxisome-proliferator-activated receptor δ activates fat metabolism to 
 72 
prevent obesity. Cell, 113(2), 159–170. https://doi.org/10.1016/S0092-
8674(03)00269-1 
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. 
(2020). Dendritic cells in cancer immunology and immunotherapy. Nature 
Reviews Immunology, 20(1), 7–24. https://doi.org/10.1038/s41577-019-0210-z 
Wearsch, P. A., & Cresswell, P. (2007). Selective loading of high-affinity peptides 
onto major histocompatibility complex class I molecules by the tapasin-ERp57 
heterodimer. Nature Immunology, 8(8), 873–881. https://doi.org/10.1038/ni1485 
Yan, M., Collins, R. F., Grinstein, S., & Trimble, W. S. (2005). Coronin-1 Function Is 
Required for Phagosome Formation. Mol Biol Cell, 16(July), 3077–3087. 
https://doi.org/10.1091/mbc.E04 
Yin, D., Ogawa, S., Kawamata, N., Tunici, P., Finocchiaro, G., Eoli, M., Ruckert, C., 
Huynh, T., Liu, G., Kato, M., Sanada, M., Jauch, A., Dugas, M., Black, K. L., & 
Koeffler, H. P. (2009). High-resolution genomic copy number profiling of 
glioblastoma multiforme by single nucleotide polymorphism DNA microarray. 
Molecular Cancer Research, 7(5), 665–677. https://doi.org/10.1158/1541-
7786.MCR-08-0270 
Zhou, X., He, C., Ren, J., Dai, C., Stevens, S. R., Wang, Q., Zamler, D., Shingu, T., 
Yuan, L., Chandregowda, C. R., Wang, Y., Ravikumar, V., Rao, A. U. K., Zhou, 
F., Zheng, H., Rasband, M. N., Chen, Y., Lan, F., Heimberger, A. B., … Hu, J. 
(2020). Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-
mediated lipid metabolism. Journal of Clinical Investigation, 130(5), 2220–2236. 
https://doi.org/10.1172/JCI131800 
Zoete, V., Grosdidier, A., & Michielin, O. (2007). Peroxisome proliferator-activated 
 73 
receptor structures: Ligand specificity, molecular switch and interactions with 
regulators. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 




Yating Li was born in Xi’an, China. She entered National University of Singapore for 
her undergraduate degree in August 2012. From August to December 2014, she 
attended George Washington University as an exchange student. She received her 
Bachelor’ degree in Life Sciences with Honors from National University of Singapore 
in June 2016. From September 2016 to June 2018, she worked as research assistant 
in Department of Physiology, Yong Loo Lin School of Medicine at National University 
of Singapore. She joined The University of Texas MD Anderson Cancer Center 
UTHealth Graduate School of Biomedical Sciences in August 2018. 
 
 
 
 
